Researching Alveolar Macrophage Improvements With Supplements in HIV

NACompletedINTERVENTIONAL
Enrollment

67

Participants

Timeline

Start Date

October 31, 2014

Primary Completion Date

December 15, 2018

Study Completion Date

December 15, 2018

Conditions
HIV-1 Infection
Interventions
DIETARY_SUPPLEMENT

Zinc and SAMe

The subjects will have the supplements dispensed at visit 2. They will be contacted weekly for the next three weeks to ensure that they are tolerating the supplements without significant side-effects. If these side-effects are significant then the dose of zinc will be decreased for all subjects to 15 mg of elemental zinc/day; if symptoms persist the SAMe dose will then be decreased by 25% (to 1200 mg/day) and then by 50% (to 800 mg/day) if necessary until the supplements are tolerated. 12 mg of zinc and 800 mg of SAMe is the lowest dose possible.

Trial Locations (1)

30308

Ponce De Leon Center, Atlanta

All Listed Sponsors
collaborator

National Institutes of Health (NIH)

NIH

collaborator

National Heart, Lung, and Blood Institute (NHLBI)

NIH

lead

Emory University

OTHER

NCT02264860 - Researching Alveolar Macrophage Improvements With Supplements in HIV | Biotech Hunter | Biotech Hunter